108 related articles for article (PubMed ID: 24361596)
1. Association between teriparatide adherence and healthcare utilization and costs among hip fracture patients in the United States.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krege J; Krohn K
Bone; 2014 Mar; 60():221-6. PubMed ID: 24361596
[TBL] [Abstract][Full Text] [Related]
2. Association between teriparatide adherence and healthcare utilization and costs in real-world US kyphoplasty/vertebroplasty patients.
Zhao Y; Johnston SS; Smith DM; McMorrow D; Krohn K; Krege J
Osteoporos Int; 2013 Sep; 24(9):2525-33. PubMed ID: 23529293
[TBL] [Abstract][Full Text] [Related]
3. Association of teriparatide adherence and persistence with clinical and economic outcomes in Medicare Part D recipients: a retrospective cohort study.
Hazel-Fernandez L; Louder AM; Foster SA; Uribe CL; Burge RT
BMC Musculoskelet Disord; 2013 Jan; 14():4. PubMed ID: 23281846
[TBL] [Abstract][Full Text] [Related]
4. The impact of teriparatide adherence and persistence on fracture outcomes.
Yu S; Burge RT; Foster SA; Gelwicks S; Meadows ES
Osteoporos Int; 2012 Mar; 23(3):1103-13. PubMed ID: 22159748
[TBL] [Abstract][Full Text] [Related]
5. Economic outcomes of exenatide vs liraglutide in type 2 diabetes patients in the United States: results from a retrospective claims database analysis.
Pelletier EM; Pawaskar M; Smith PJ; Best JH; Chapman RH
J Med Econ; 2012; 15(6):1039-50. PubMed ID: 22533526
[TBL] [Abstract][Full Text] [Related]
6. Clinical and economic characteristics of hip fracture patients with and without muscle atrophy/weakness in the United States.
Zhao Y; Chen SY; Lee YC; Wu N
Arch Osteoporos; 2013; 8():127. PubMed ID: 23532737
[TBL] [Abstract][Full Text] [Related]
7. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of hip fracture patients with and without muscle atrophy/weakness: predictors of negative economic outcomes.
Cui Z; Schoenfeld MJ; Bush EN; Chen Y; Burge R
J Med Econ; 2015 Jan; 18(1):1-11. PubMed ID: 25271379
[TBL] [Abstract][Full Text] [Related]
9. Real-world clinical and economic outcomes for daily teriparatide patients in Japan.
Burge R; Sato M; Sugihara T
J Bone Miner Metab; 2016 Nov; 34(6):692-702. PubMed ID: 26661475
[TBL] [Abstract][Full Text] [Related]
10. Impact of disease severity on healthcare costs in patients with chronic hepatitis C (CHC) virus infection.
Gordon SC; Pockros PJ; Terrault NA; Hoop RS; Buikema A; Nerenz D; Hamzeh FM
Hepatology; 2012 Nov; 56(5):1651-60. PubMed ID: 22610658
[TBL] [Abstract][Full Text] [Related]
11. Cost and utilization outcomes of opioid-dependence treatments.
Baser O; Chalk M; Fiellin DA; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S235-48. PubMed ID: 21761950
[TBL] [Abstract][Full Text] [Related]
12. Resource utilization and costs following hospitalization of patients with chronic heart failure in the US.
Korves C; Eldar-Lissai A; McHale J; Lafeuille MH; Hwa Ong S; Sheng Duh M
J Med Econ; 2012; 15(5):925-37. PubMed ID: 22502902
[TBL] [Abstract][Full Text] [Related]
13. Cost, healthcare resource utilization, and adherence of individuals with diabetes using U-500 or U-100 insulin: a retrospective database analysis.
Eby EL; Wang P; Curtis BH; Xie J; Haldane DC; Idris I; Peters AL; Hood RC; Jackson JA
J Med Econ; 2013; 16(4):529-38. PubMed ID: 23363330
[TBL] [Abstract][Full Text] [Related]
14. Cost and consequences of noncompliance with osteoporosis treatment among women initiating therapy.
Modi A; Siris ES; Tang J; Sen S
Curr Med Res Opin; 2015 Apr; 31(4):757-65. PubMed ID: 25661017
[TBL] [Abstract][Full Text] [Related]
15. Osteoporotic fractures and associated hospitalizations among patients treated with teriparatide compared to a matched cohort of patients not treated with teriparatide.
Boytsov N; Zhang X; Sugihara T; Taylor K; Swindle R
Curr Med Res Opin; 2015; 31(9):1665-75. PubMed ID: 26121328
[TBL] [Abstract][Full Text] [Related]
16. Retrospective database study to assess the economic impact of hip fracture in the United Kingdom.
Lambrelli D; Burge R; Raluy-Callado M; Chen SY; Wu N; Schoenfeld MJ
J Med Econ; 2014 Nov; 17(11):817-25. PubMed ID: 25164473
[TBL] [Abstract][Full Text] [Related]
17. Impact of infliximab adherence on Crohn's disease-related healthcare utilization and inpatient costs.
Carter CT; Waters HC; Smith DB
Adv Ther; 2011 Aug; 28(8):671-83. PubMed ID: 21818671
[TBL] [Abstract][Full Text] [Related]
18. Pharmacotherapy adherence and costs versus nonpharmacologic management in overactive bladder.
Pelletier EM; Vats V; Clemens JQ
Am J Manag Care; 2009 Mar; 15(4 Suppl):S108-14. PubMed ID: 19355799
[TBL] [Abstract][Full Text] [Related]
19. Alcohol dependence treatments: comprehensive healthcare costs, utilization outcomes, and pharmacotherapy persistence.
Baser O; Chalk M; Rawson R; Gastfriend DR
Am J Manag Care; 2011 Jun; 17 Suppl 8():S222-34. PubMed ID: 21761948
[TBL] [Abstract][Full Text] [Related]
20. The economic burden of lung cancer and the associated costs of treatment failure in the United States.
Kutikova L; Bowman L; Chang S; Long SR; Obasaju C; Crown WH
Lung Cancer; 2005 Nov; 50(2):143-54. PubMed ID: 16112249
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]